Provide protocol development and research laboratory assays relative to protocol 14-0112, a phase II double-blind randomized placebo controlled trial to evaluate the safety, reactogenicity, and…
Ended Awarded Last action
- Contract number
- HHSN27200012
- Awardee
-
Saint Louis University UEI JNBLLTBTLLD8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $448,081
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2012144 Solicitation number
- Vaccine and treatment evaluation units (vteu) Award Notice · Posted Mar 29, 2012
- Contract value 100% obligated
- $448,081.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- St. Louis, MO 63103, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $394,400 | |
| Funding Only Action | -$32,093 | |
| Original award | $53,681 |
About this award
This federal contract award, valued at $448,081.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Saint Louis University, a private Jesuit research university. The contract is for the development of protocols and laboratory assays related to a Phase II clinical trial to evaluate the safety, reactogenicity, and immunogenicity of an influenza A/H7N9 vaccine. This contract is part of the Vaccine and Treatment Evaluation Units (VTEU) program, which is a major initiative at NIAID focused on the evaluation of vaccine and treatment candidates. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. Saint Louis University has a strong track record of securing federal contracts and grants, particularly in the areas of healthcare, medical research, and education.
Description
Provide protocol development and research laboratory assays relative to protocol 14-0112, a phase II double-blind randomized placebo controlled trial to evaluate the safety, reactogenicity, and immunogenicity of one or two doses of m-001 followed by one or two doses of an influenza a/H7N9 vaccine in healthy volunteers.
Quick answers
Who was awarded contract HHSN27200012?
HHSN27200012 was awarded to Saint Louis University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 14, 2016.
How much is contract HHSN27200012 worth?
The government has obligated $448,081 on HHSN27200012.
Is contract HHSN27200012 an order under another contract?
Yes. HHSN27200012 is a delivery order under HHSN272201300021I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).
Was contract HHSN27200012 competed?
The extent of competition for HHSN27200012 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award